Пищевод Барретта как предраковое состояние, особенности экспрессии опухолевых маркеров
Диссертация
Результаты проведенного исследования и анализ данных литературы показывают, что длительное течение ГЭРБ может приводить к последовательным изменениям слизистой нижней трети пищевода. На первом этапе, под воздействие повреждающих факторов в пласте плоского эпителия развивается хроническое воспаление в виде ГЭРБ-эзофагита (15 случаев). При продолжающемся ГЭР нарушается дифференцировка покровного… Читать ещё >
Список литературы
- Введение в молекулярную медицину//Пальцев М.А.—- М: Медицина, 2004. — 496.
- Давыдов М.И., Тер-Ованесов М.Д., Стилиди И. С., Дыхно А. Ю. и др. Пищевод Барретта: от теоретических основ к практическим рекомендациям.// Практическая онкология 2003 — Т.4 — № 2 — С. 109−119.
- Елисеев В. Г., Соединительная ткань. Гистофизиологические очерки, М., 1961- Метаплазия тканей. Сб. ст., М., 1970.
- Ивашкин В.Т. и др. Профилактика и лечение хронических заболеваний верхних отделов желудочно-кишечного тракта. — М.: МЕДпресс-информ 2002 — С.49−66.
- Ивашкин В.Т. Современная гастроэнтерология и предопухолевые заболевания пищеварительной системы. // Российский журнал гастроентерологии, гепатологии, колопроктологии 2002 — № 3.
- Ивашкин В.Т., Трухманов А. С. Болезни пищевода. М.: Триада-X — 2000.
- Ивашкин В.Т., Трухманов А. С. Пищевод Барретта: эпидемиология, патогенез, течение и профилактика. // Врач 2001 — № 3 -С. 11−13.
- Ивашкин В.Т., Трухманов А. С. Программное лечение гастроэзофагеальной рефлюксной болезни в повседневной практике врача. // Российский журнал гастроентерологии, гепатологии, колопроктологии — 2003 № 6.
- Ивашкин В.Т., Шептулин А. А. Избранные лекции по гастроэнтерологии. — М.: МЕДпресс-информ — 2002 — С.49−66.
- Ивашкина В.Т., Комарова Ф. И., Рапопорта С.И Краткое руководство по гастроэнтерологии.// М.: М-Вести 2001 — С.82−88.
- Коган Е. А., Парамонова Н. Б., Демура С. А., Попова Е. Н. Цитогенетические варианты дисрегенераторных и предраковых измененийэпителия при хронических воспалительных заболеваниях легких.//Архив патологии 2003.65(4): 12−8.
- Коган Е.А. Молекулярно-генетические основы канцерогенеза. //Российский журнал гастроэнтерологии, гепатологии, колопроктологии — 2002 T. XII — № 3 — С. 32−36.
- Комаров Ф.И., Гребенев A.JL, Шептулин А. А. Руководство по гастроэнтерологии. М.: Медицина 1995 — Т. 1−3.
- Кононов А.В. Гастроэзофагеальная рефлюксная болезнь: взгляд морфолога на проблему. Рос. журн. гастроэнтерол., гепатол., колопроктол., 2004, 1,71−77.
- Allison P. R., Johnston A. S. // Thorax. — 1953. — Vol. 8. P. 87 101.
- Antonioli DA. Esophagus. In: Henson DE, Albores-Saavedra J, eds. Pathology of Incipient Neoplasia. Philadelphia, Pa: WB Saunders Co- 1993−64−84.
- Apoptosis Catalog R and D SYSTEMS -2000/2001.
- Arends M.J., McGregor A.H., Wyllie A.H. Apoptosis is inversely-related to necrosis and determines net growth in tumours bearing constitutively expressed myc, ras and HPV oncogenes.// Am. J. Pathol. 1994. — Vol. 144. — P. 1045−1057.
- Baljeet S, Triadafilopoulos G. Acid and bile-induced PGE2 release and hyperproliferation in Barrett’s esophagus are COX-2 and PKC-e dependent.// Am J Physiol (Gastrointest Liver Physiol) 2002 — V.283 — P. 327 334.
- Barrett MT, Sanchez CA, Galipeau PC, et al. Allelic loss of 9p21 and mutation of the CDKN2/pl6 gene develop as early lesions during neoplastic progression in Barrett’s esophagus. Oncogene. 1996- 13:1867−1873.
- Barrett N. R. // Brit. J. Surg. — 1950. Vol. 38. — P. 175—182.
- Barrett N. R. // Surgery. 1957. — Vol. 41. — P. 881—894.
- Beilstein M, Silberg D. Cellular and molecular mechanism responsible for progression of Barrett’s metaplasia to esophageal carcinoma.//Gastroenterol Clin N Am 2002 — V.31 — P.461−479.
- Bersentes K- Fass R- Padda S- Johnson C- Sampliner RE Prevalence of Barrett’s esophagus in Hispanics is similar to Caucasians. Dig Dis Sci 1998 May-43(5): 103 8−41.
- Blount PL, Ramel S, Raskind WH, et al. 17p allelic deletions and p53 protein overexpression in Barrett’s adenocarcinoma. Cancer Res. 1991−51:5482−5486.
- Boch J.A.- Shields H.M. — Antonioli D.A. — Zwas F.- Sawhney R.A.- Trier J.S. Distribution of cytokeratin markers in Barrett’s specialized columnar epithelium.// Gastroenterology 1997, vol. 112, № 3, pp. 760−765.
- Cameron AJ- Zinsmeister AR- Ballard DJ- Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology 1990 Oct-99(4):918−22.
- Carvalho CA. Studies on the microscopic anatomy of the veins in the esophagogastric transition zone in man. Rev Hosp Clin Fac Med Sao Paulo 1966- 21: 113−128.
- Casson AG, Kerkvliet N, O’Malley F. Prognostic value of p53 protein in esophageal adenocarcinoma.// J Surg Oncol. 1995−60:5−11.
- Chen X, Yang C. Esophageal adenocarcinoma: a review and perspectives on the mechanism of carcinogenesis and chemoprevention.//Carcinogenesis 2001 — V.22 — N8 — P. 1119−1129.
- Clickman JN, Chen JJ, Wang HH, et al. Phenotypic characteristics of a distinctive multilayered epithelium suggests that it is a precursor in thedevelopment of Barrett’s esophagus.//Am J Surg Pathol 2001 — V.25 — P. 569 578.
- Cook MB- Wild CP- Forman D A systematic review and metaanalysis of the sex ratio for Barrett’s esophagus, erosive reflux disease, and nonerosive reflux disease. Am J Epidemiol. 2005 Dec 1−162(11): 1050−61.
- Csendes A- Smok G- Burdiles P- Prevalence of Barrett’s esophagus by endoscopy and histologic studies: a prospective evaluation of 306 control subjects and 376 patients with symptoms of gastroesophageal reflux. Dis Esophagus 2000−13(1):5−11.
- Cucchiara S., Santamaria F., Andreotti M. R. et al. // Arch. Dis. Childh. 1991. — Vol. 66. — P. 617−622.
- Delaney ВС. Prevalence and epidemiology of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2004−20.
- Dvorakova et al. Apoptosis resistance in Barrett’s esophagus: ex vivo bioassay of live stressed tissues. The American journal of gastroenterology 2005, VI00(2) pp 424−431.
- Fagundes RB, de Barros SG, Putten AC, et al.: Occult dysplasia is disclosed by Lugol chromoendoscopy in alcoholics at high risk for squamous cell carcinoma of the esophagus.// Endoscopy 1999,31:281−285.
- Fenoglio, Preiser. Gastrointestinal pathology: an atlas and text. Lippincott Williams and Wilkins 2008- 1296: p85−134.
- Fillies Т., Werkmeister R., Packeisen J. Cytokeratin 8/18 expression indicates a poor prognosis in squamous cell carcinomas of the oral cavity .//BMC Cancer 2006, 6:10.1186/1471−2407−6-10.
- Fitzgerald R. С. Molecular basis of Barrett’s oesophagus and oesophageal adenocarcinoma.//Gut 2006−55:1810−1818.
- Flejou JF, Potet F, Muzeau F, et al. Overexpression of p53 protein in Barrett’s syndrome with malignant transformation.//J Clin Pathol. 1993−46:330−333.
- Gerson LB- Shetler K- Triadafllopoulos G Prevalence of Barrett’s esophagus in asymptomatic individuals.//Gastroenterology 2002 Aug- 123(2):461−7.
- Gillen P., Keeling P., Byrne P. J. et al. // Brit. J. Surg. — 1988.- Vol. 75. P. 540−543.
- Giuli R., Siewert J., Couturier D. et al Barrett’s Esophagus. /- Paris: John Libbey Eurotext 2003 — V. l-2.r
- Gyorffy H., Holczbauer A., Nagy P. Claudin expression in Barrett’s esophagus and adenocarcinoma.// Virchows Arch (2005) 447: 961−968.
- Halm U, Tannapfel A, Breitung et al. Apoptosis and cell proliferation in the metaplasia-dysplasia-carcinoma sequence of Barrett’s esophagus.//Hepatogastroenterology 2000 — V. 47(34) — P. 962−966.
- Hamilton S., Aaltonen L. WHO classification of tumours. Tumours of digestive system. IARCpress Lyon 2000: 314: 9−26.
- Hamilton SR. Adenocarcinoma in Barrett’s esophagus. In: Whitehead R, ed. Gastrointestinal and Esophageal Pathology. Edinburgh, Scotland: Churchill Livingstone- 1989:683−706.
- Hamilton SR. Reflux esophagitis and Barrett’s esophagus. In: Goldman H, Appelman HD, Kaufman N, eds. Gastrointestinal Pathology. Baltimore, Md: Williams & Wilkins- 1990:11−68.
- Hanahan D, Weinberg R. The hallmarks of cancer.//Cell 2000- 100:57−70.
- Heinzelman-Shwarz, Gardiner-Garden M, Henshall SM Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAMin metaplastic ovarian epithelium and ovarian cancer.// Clin Cancer Res 2004 Jul l-10(13):4427−36.
- Ho 11 stein MC, Metcalf RA, Welsh JA, et al. Frequent mutation of the p53 gene in human esophageal cancer.//Proc Natl Acad Sci USA. 1990−87:9958−9961.
- Hong MK, Laskin WB, Herman BE. Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett’s esophagus.//Cancer. 1995 Jan 15−75(2):423−9.
- Hughes SJ, Nambu Y, Soldes OS, et al. Fas/APO-l (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma.// Cancer Res. 1997−57:5571−5578.
- Hughes SJ, Nambu Y, Soldes OS, et al. Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma. Cancer Res. 1997−57:5571−5578.
- Ishag S., Jankowski JA. Barretts metaplasia: clinical implications.// World J Gastroenterol 2001 — V.7(4) — P. 563−565.
- Jankowski J, Sharma P. Review article: approaches to Barrett’s esophagus treatment — the role of proton pump inhibitors and other interventions.// Aliment Pharmacol Ther. 2004 — V. 19 — P.54−59.
- Jankowski JA, Wright NA, Meltzer SJ, Triadafllopoulos G, et al. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.//Am J Pathology 1999 — V. 154 — № 4 — P.965−973.
- Jochem VJ et al. Familial Barrett’s esophagus associated with adenocarcinoma. Gastroenterology 1992:102:1400−2.
- Johnson AH, Frierson H, Zaika A et al. Expression of tight junction protein claudin-7 is an early event in gastric tumorogenesis. Am J Path, 2005. Vol 167:.P577−584.
- Jovov В., Christina M. Van Itallie, Shaheen N. J. Claudin-18: a dominant tight junction protein in Barrett’s esophagus and likely contributor toits acid resistance.//Am J Physiol Gastrointest Liver Physiol 293: G1106-G1113, 2007.
- Katada N, Hinder RA, Smyrk TC, et al. Apoptosis is inhibited early in the dysplasia-carcinoma sequence of Barrett esophagus.//Arch Surg. 1997−132:728−733.
- Konecny GE, Agarwal R, Keeney GA, Claudin-3 and claudin-4 expression in serous papillary, clear-cell, and endometrioid endometrial cancer.// Gynecol Oncol. 2008 May-109(2):263−9. Epub 2008 Mar 7.
- Kozarek R, Inoue H, Sakai P, et al.: Lugol chromoendoscopy for esophageal squamous cell cancer.//Endoscopy 2001,33:75−79.
- Krishnadath K., Reid BJ., Kenneth KW. Biomarkers in Barrett esophagus. // Mayo Clin Proc. 2001 — V.76 — P. 438−446.
- Kumble S, Omary MB, Cartwright CA, et al. Src activation in malignant and premalignant epithelia of Barrett’s esophagus.// Gastroenterology. 1997- 112:348−356.
- Lambert R, Sharma P. Paris Workshop on Columnar Metaplasia.// Endoscopy 2005- 37−879−920.
- Lee SK, Moon J, Park S W. Loss of the tight junction protein claudin 4 correlates with histological growth-pattern and differentiation in advanced gastric adenocarcinoma// Oncology Reports, 2005. 13:193−199.
- Messmann H, Schlottmann K: Role of endoscopy in the staging of esophageal and gastric cancer.//Semin Surg Oncol 2001,20:78−81.
- Mitosis and Apoptosis. Matters of life and death./ edit. Bowen I.D., Bowen S.M., Jones A.H. 1st ed. — 1997. — Chapman and Hall. — London. — pp. 182.
- Moll R. Cytokeratins as markers of differentiation in the diagnosis of epithelial tumors. Ch 7 Subcellular biochemistry, V 31 Intermediate filaments, edited by Herrmann and Harris. Plenum Press, New York, 1998. P-205−262.
- Montgomery E, Mamelak AJ, Gibson M. Overexpression of claudin proteins in esophageal adenocarcinoma and its precursor lesions.//Appl Immunohistochem Mol Morphol. 2006 Mar-14(l):24−30.
- Murata Y, Suzuki S, Mitsunaga A, et al.: Endoscopic ultrasound in diagnosis and mucosal resection for early esophageal cancer.//Endoscopy 1998,30:A44-A46.
- National Center for Biotechnology Information. Definition, epidemiology, and pathogenesis of GERD. Available at: www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=surg.section.310. Accessed September 2005.
- Paull A. The histologic spectrum of Barrett’s esophagus. // N Engl J Med, 1976. 29:476−480.
- Polkowski W, van Lanschot JJ, Ten Kate FJ. The value of p53 and Ki67 as markers for tumour progression in the Barrett’s dysplasia-carcinoma sequence.// Surg OncoL 1995 Jun-4(3): 163−71.
- Ramel S, Reid BJ, Sanchez CA, et al. Evaluation of p53 protein expression in Barrett’s esophagus by two-parameter flow cytometry.// Gastroenterology. 1992- 102:1220−1228.
- Ray GS, Lee JR, Nwokeji K, et al. Increased immunoreactivity for Rabll, a small GTP-binding protein, in low-grade dysplastic Barrett’s epithelia. //Lab Invest. 1997−77:503−511.
- Reid В J, Blount PL, Rubin CE. Flow cytometric and histological progression to malignancy in Barrett’s esophagus: prospective endoscopic surveillance of a cohort.//Gastroenterology 1992 — V. 102 — P. 1212−1219.
- Reid BJ, Weinstein WM, Lewin KJ, et al. Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett’s esophaguswithout grossly recognizable neoplastic lesions.// Gastroenterology. 1988−94:81−90.
- Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical implications.// Hum Pathol. 1983−14:931−968.
- Robbins Pathologic Basis of Disease / Cotran, Kumar, Collins. — 6. — Philadelphia: W.B. Saunders Company, 1999. — 1426.
- Ronkainen J- Aro P- Storskrubb T Prevalence of Barrett’s Esophagus in the General Population: An Endoscopic Study.//Gastroenterology. 2005 Dec-129(6):1825−31.
- Rothery GA, Day DW. Intestinal metaplasia in endoscopic biopsy specimens of gastric mucosa.//J Clin Pathol 1985−38:613−621
- Sampliner RE A Population Prevalence of Barrett’s Esophagus-Finally.// Gastroenterology. 2005 Dec- 129(6):2101−3.
- Schido Y. et al. Progress in understanding the molecular pathogenesis of human lung cancer.//Biochimica et Biophysica Acta 1998. -Vol.1378.-P. 21−59.
- Schneider PM, Casson Ag, Levin B, et al. Mutations of P53 in Barrett’s esophagus and Barrett’s cancer: a prospective study of 98 cases.// J Thorac Cardiovasc Surg. -1996 -V. 111 P. 323−331.
- Shaheen N. Is there a «Barretts Iceberg?» // Gastroenterology -2002 V. 123(2) — P.636−638.
- Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett’s esophagus?// Gastroenterology 2000 — V. 119 — N.2 — P. 333−338.
- Sharma P., McQuaid K., Dent J., Fennerty M. et al. AGA Chicago Workshop. A critical review of the diagnosis and management of Barrett’s esophagus: the AGA Chicago Workshop.// Gastroenterology 2004 — V.127 -P. 310−330.
- SharmaP. Sampliner R. Barrett’s esophagus and Esophageal adenocarcinoma Second edition. 2006 Blackwell Publishing 300: 1−7.
- Smith RR, Hamilton SR, Boitnott JK, et al. The spectrum of carcinoma arising in Barrett’s esophagus: a clinicopathologic study of 26 patients. //Am J Surg Pathol. 1984−8:563−573.
- Soslow RA, Ying L, Altorki NK. Expression of acidic fibroblast growth factor in Barrett’s esophagus and associated esophageal adenocarcinoma.//J Thorac Cardiovasc Surg. 1997−114:838−843.
- Spechler S, Goyal R. The columnar-lined esophagus, intestinal metaplasia and Norman Barrett.// Gastroenterology. 1996−110: 614−621.
- Spechler SJ. Clinical practice. Barrett’s Esophagus.// N Engl J Med 2002 Mar 14−346(11):836−42.
- Spechler SJ. The columnar-lined esophagus: history, terminology, and clinical issues.//Gastroenterol Clin North Am 1997 — V.26 — P. 455−466.
- Swami S, Kumble S, Triadafllopoulos G, et al. E-cadherin expression in gastroesophageal reflux disease, Barrett’s esophagus, and esophageal adenocarcinoma: an immunohistochemical and immunoblot' study.// Am J Gastroenterol. 1995−90:1808−1813.
- Ward EM- Wolfsen HC- Achem SR Barrett’s Esophagus Is Common in Older Men and Women Undergoing Screening Colonoscopy Regardless of Reflux Symptoms.// Am J Gastroenterol. 2006 Jan-101(l):12−7.
- Weston AP., Sushanta K. p53 protein’overexpression in low grade dysplasia (LGD) in barrett’s esophagus: Immunohistochemical marker predictiveof progression.// American Journal of Gastroenterology, May 2001 Volume 96 P-1355.
- Woelfle U, Sauter G, Santjer S. Down-regulated expression of cytokeratin 18 promotes progression of human breast cancer. Clin Cancer Res 10(8):2670−4. 2004 Apr 15
- Woolf G., Riddel R., Irvine E, et al. A study of examine agreement between endoscopy and histology for the diognosis of columnar-lined (Barrett's) esophagus. Gastrointest Endosc.1989- 35:541−544.
- Younes M, Lebovitz RM, Lechago LV, et al. p53 protein accumulation in Barrett’s metaplasia, dysplasia and adenocarcinoma: a follow-up study .//Gastroenterology. 1993−105:1637−1642.